Latest News
Micronoma Welcomes Esteemed Clinical Oncologist to Scientific Advisory Board
Jennifer Wargo, M.D., leads research on link between microbiome and cancer treatment and recently co-authored Science review with Micronoma founders San Diego, Calif. (April 6, 2021) - San Diego, Calif. Micronoma, the first cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, today announced that Jennifer Wargo, M.D., M.M.Sc., Professor, Surgical Oncology & Genomic Medicine at The...
Upcoming Conferences
Inaugural Microbiome Leaders Conference 3/24 - Finding New Avenues of Cancer Cures and Diagnostic by Studying Tissue and Circulating Microbiome
Microbiome Movement, Drug Development 6/26-7/1 - "Tissue and Circulating microbiomes - the new frontier"
Precision Medicine World Conference 2022 January 2022 - "Cancer Microbiome and Diagnostic Application"
Micronoma Raises $3.5 Million in Convertible Note Financing
Investors more than double funding base for cancer microbiome diagnostic company to accelerate go-to-market timeline six months after seed February 17, 2021 -- San Diego, Calif. Micronoma, the first cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, today announced the closing of $3.5 million in convertible debt financing. The contributions came from existing investor, US-based SymBiosis,...
Micronoma Establishes Scientific Advisory Board
International oncology, microbiome and drug discovery expertise synergize to guide unique early cancer detection startup SAN DIEGO, Dec. 9, 2020 /PRNewswire/ -- Micronoma, the first cancer detection biotech company that uses signals from the tumor-related microbiome...
Micronoma Expands Executive Team and Operations
Innovative early cancer detection company establishes headquarters and adds three key executive positions San Diego, Calif. (November 5, 2020). Micronoma, an early-stage cancer detection biotech company seeking to develop and commercialize a minimally-invasive, unique...
Micronoma Appoints Magda Marquet Chairman of the Board
Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- Micronoma, an early stage cancer-detection start-up seeking to develop and commercialize a minimally-invasive, unique...
Micronoma Launches with $3 Million Seed Funding
For Immediate Release Media Contact: Celia Sepulveda, Celia.Sepulveda@Micronoma.com, 858.337.1326 Micronoma Launches with $3 Million Seed Funding First early cancer-detection company to use microbial biomarkers in diagnostics San Diego, Calif....
Microbial DNA in Patient Blood May be Tell-Tale Sign of Cancer
From a simple blood draw, microbial DNA may reveal who has cancer and which type, even at early stages When Gregory Poore was a freshman in college, his otherwise healthy grandmother was shocked to learn that she had late-stage pancreatic cancer. The condition was...
UCSD team, and Micronoma founders, publish Nature paper identifying nucleic acid-based, tumor-specific microbial signatures in the blood, suggesting a new diagnostic approach.
Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Systematic characterization of the cancer microbiome provides the opportunity to develop techniques that exploit non-human, microorganism-derived molecules in the diagnosis of a major human disease.
Micronoma to Present at Biocom’s 10th Annual Global Life Science Partnering Conference
Micronoma will be presenting at Biocom this year. Go to Biocom Micronoma San Diego, CA, USA info@micronoma.comlinkedin
Contact Us
If you have questions or would like to learn more, please email us at info@micronoma.com or contact us.
Micronoma
6342 Ferris Square
San Diego, CA 92121